Gliomas form a heterogeneous group of tumors of the central nervous system (CNS) and are
traditionally classified based on histologic type and malignancy grade. Most gliomas, the …

Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1 and IDH2, are frequently
mutated in multiple types of human cancer. Mutations targeting IDH1 and IDH2 result in …

Glioblastomas are heterogeneous neoplasms that are driven by complex signalling
pathways, and are among the most aggressive and challenging cancers to treat. Despite …

The term long‐term epilepsy associated tumor (LEAT) encompasses lesions identified in
patients investigated for long histories (often 2 years or more) of drug‐resistant epilepsy …

In the management of diffuse gliomas, the identification and removal of tumor at the
infiltrative margin remains a central challenge. Prior work has demonstrated that …

Background Identification of genetic changes in CNS tumors is important for the appropriate
clinical management of patients. Our objective was to develop a next-generation …

A number of key mutations that affect treatment and prognosis have been identified in
human gliomas. Two major ways to identify these mutations in a tumor sample are direct …

Glioblastoma is the most fatal brain cancer found in humans. Patients suffering from
glioblastoma have a dismal prognosis, with a median survival of 15 months. The tumor may …

Background Several variables are associated with the likelihood of isocitrate
dehydrogenase 1 or 2 (IDH1/2) mutation in gliomas, though no guidelines yet exist for when …

Low-grade gliomas (LGG) constitute grades I and II tumors of astrocytic and grade II tumors
of oligodendroglial lineage. Although these tumors are typically slow growing, they may be …